---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-013237"
form_type: "8-K"
ticker: "TECX"
cik: "0001681087"
company_name: "Tectonic Therapeutic, Inc."
filed_at: "2023-03-23T23:59:59+00:00"
generated_at: "2026-06-17T18:42:36.970066+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# AVROBIO reports Q4 net loss $25.0M, full-year 2022 loss $105.9M; cash $92.6M

## Summary
- Net loss of $25.0M in Q4 2022 vs $28.2M in Q4 2021; full year loss $105.9M vs $119.1M.
- R&D expenses $18.1M (Q4) and $72.2M (FY); G&A expenses $7.1M (Q4) and $33.2M (FY).
- Cash and equivalents $92.6M as of Dec 31, 2022, down from $189.6M a year earlier; expects to fund operations into Q1 2024.
- Plan to initiate registrational global Phase 2/3 trial (Guard3) for Gaucher disease type 3 in H2 2023, subject to regulatory alignment.
- Collaborator-sponsored Phase 1/2 trial for cystinosis completed dosing; late-stage activities planned H2 2023.

## SEC filing metadata
- accession: 0001140361-23-013237
- form_type: 8-K
- ticker: TECX
- cik: 0001681087
- company_name: Tectonic Therapeutic, Inc.
- filed_at: 2023-03-23T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1681087/000114036123013237/0001140361-23-013237-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1681087/000114036123013237/brhc10050093_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-013237
- JSON: https://secwatch.observer/filing/0001140361-23-013237.json
- Plain text: https://secwatch.observer/filing/0001140361-23-013237.txt

## Key facts
- Earnings Releases
  Tectonic Therapeutic, Inc. reported financial results for the three months and year ended December 31, 2022.
  - Period: the three months and year ended December 31, 2022
  - Result: reported results
  source text: On March 23, 2023, AVROBIO, Inc. (the “Company”) issued a press release containing information about the Company’s results of operations for the three months and year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1681087/000114036123013237/0001140361-23-013237-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.